rAAV Production Full Service, Medium Scale


  • Catalog #: SL100861
  • Unit Size: 0.2 mL (>1X1013 VG/mL)

rAAV Production Full Service, Medium Scale

Features:
- Nonpathogenic with least immune response.
- Excellent gene delivery efficiency in most cell types including dividing and non-dividing or primary cells.
- Persistent transgene expression.

- Multiple serotypes (AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-8, AAV-9, AAV-DJ/8 and AAV-DJ).

Large AAV cis vector inventory for constructing AAV cis plasmid with a specific promoter and reporter:

 Single promoter rAAV cis vector

 Dual promoter rAAV cis vector

          Promoterless
          CMV
          CAG
          H1
         
U6
          Synapsin
          UBC

          EF1α
          CBh
         
TRE-miniCMV
          CMVtight

          ALB(1.4)

          MHCK7
          ApoE/AAT1

          CaMKII
          ELA1
          Enh358MCK
          cTNT
          GFAP
          MBP
          SST
          TBG

          αMHC
          hRPE
          mIP1
          tMCK





















 
 

           Promoterless
           CMV
           CAG
           H1
          
U6
           Synapsin
           UBC

           EF1α
           CBh

          
TRE-miniCMV
           CMVtight

           ALB(1.4)

           MHCK7

           ApoE/AAT1
           CaMKII
           ELA1
           Enh358MCK
           cTNT
           GFAP
           MBP
           SST
           TBG

           αMHC
           hRPE
           mIP1
           tMCK

CMV
CAG
H1

U6
Synapsin
UBC

EF1α
CaMKII
cTNT
GFAP
TRE-miniCMV
CMVtight
MHCK7










 

eGFP
RFP
mRFP
mCherry
tdTOMATO
TurboGFP
eYFP
Venus
Luc
LacZ
TRE-miniCMV
CMVtight
MHCK7

 


Service Description:
- Cloning your gene of interest (GOI) into AAV cis vector.
- rAAV cis plasmid large prep.
- rAAV packaging
in 1xcell stack.
- rAAV purification via advanced 2xCsCl ultra-centrifugation.
-
Desalting, filter sterilization and AAV titration via qPCR.

rAAV Serotypes We Offer:
AAV-1, AAV-2, AAV-3, AAV-4, AAV-5, AAV-6, AAV-7, AAV-8, AAV-9, AAV-PHP.B, AAV-PHP.eB, AAV-DJ/8 and AAV-DJ.

Required Materials: A NCBI accession # or gene symbol or plasmid DNA carrying your gene of interest (GOI).

Turnaround Time: 2 ~ 3 weeks.

Deliverables: >0.2 mL (4x 50
µL) of super purified in vivo grade rAAV vector at >1E+13 VG/mL*.


We offer discount for new customer, please request a quote with us today.

 

Super High Yield:
With our proprietary genetically engineered AAV·HT™ packaging cell and a advanced purification approach, the rAAV yield is easy to reach super high level--------total 1E+15 VG. For super high level rAAV production up to 1E+15 VG total, please contact us to request a quote.
 


Figure 1. A comparison of purity and infectivity of rAAV vectors from different sources showing super purified and super infectious (close to clinical trial grade) rAAV vector prepared via our advanced double CsCl ultra-centrifugation approach. 
A. rAAV vectors (total 1E+9 VG per lane)  from different sources were resolved on SDS-PAGE followed by silver staining.  Lane 1: GMP manufactured rAAV vector from CHOP; Lane 2: rAAV prepared via our advanced 2xCsCl ultra-centrifugation approach; Lane 3: rAAV from Vector Core of BCM; Lane 4: rAAV from our competitor "V"; Lane 5: rAAV from our competitor "C"; Lane 6: Protein marker.
B. Super infectious rAAV vector prepared via advanced double CsCl ultra-centrifugation.  Left panel: rAAV9-GFP (total 5E+9 VG) from our competitor "V" injected to mouse eye; Right panel: rAAV-9-GFP (total 5E+9 VG) purified via advanced 2xCsCl ultra-centrifugation injected to mouse eye. 



Figure 2. A comparison of infectivity of rAAV vectors from different sources showing super purified rAAV prepared via advanced double CsCl ultra-centrifugation approach is super infectious.
rAAV1-GFP (total 2E+9 VG) from different sources were injected to mouse muscle tissue.  The GFP fluorescence was visualized 3 weeks post injection.  A. rAAV1-GFP from our competitor "V"; B. rAAV1-GFP from our pre-made rAAVs stock purified via advanced double CsCl ultra-centrifugation.  C. Quantification data showed that our super purified rAAV (bar 2) is ~ 9 times more infectious than that (bar 1) prepared via conventional CsCl ultra-centrifugation.  


* Final viral yield may depend on the nature of transgene.




Copyright © 2017 SignaGen Laboratories. All Rights Reserved.